Načítá se...
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States
INTRODUCTION: Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no...
Uloženo v:
| Vydáno v: | PLoS One |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7660549/ https://ncbi.nlm.nih.gov/pubmed/33180804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0241989 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|